Streetbeat News

LSB

LakeShore Biopharma Co., Ltd

https://www.ysbiopharm.com

Industry

Biotechnology

LakeShore Biopharma Co., Ltd, a biopharmaceutical company, engages in discovering, developing, manufacturing, and commercializing of vaccines and therapeutic biologics for infectious diseases and cancer. The company develops a proprietary PIKA immunomodulating technology platform and a series of product targeting PIKA rabies vaccine, PIKA recombinant COVID-19 vaccine, and PIKA YS-ON-001. It operates in China, the United States, Singapore, the United Arab Emirates, and the Philippines. The company was formerly known as YS Biopharma Co., Ltd. and changed its name to LakeShore Biopharma Co., Ltd in May 2024. LakeShore Biopharma Co., Ltd was founded in 2002 and is based in Beijing, China.

Open

2.33

Mkt cap

48M

Volume

4.6K

High

2.64

P/E Ratio

-0.45

52-wk high

11.20

Low

2.33

Div yield

N/A

52-wk low

1.88

LakeShore Biopharma (Nasdaq: LSB) announced a criminal investigation by the Shenyang Municipal Public Security Bureau in China involving its former chairman, Yi Zhang. The company is a global leader in vaccines and therapeutic biologics.

Portfolio Pulse from

December 13, 2024 | 1:15 am

LSB Industries has released its 2023 Sustainability Report, emphasizing its commitment to sustainability and clean energy transition through low carbon products.

Portfolio Pulse from

December 03, 2024 | 9:30 pm

LSB Industries, Inc. has appointed John Chandler as an independent member of its Board of Directors, effective November 7, 2024. Chandler, with over 30 years of experience in the energy sector, will also join the audit committee.

Portfolio Pulse from

November 11, 2024 | 9:30 pm

LakeShore Biopharma has regained compliance with Nasdaq's minimum bid price requirement, as confirmed by a notice from Nasdaq's Listing Qualifications Department.

Portfolio Pulse from Benzinga Newsdesk

October 29, 2024 | 12:39 pm

LakeShore Biopharma has received approval in China for a Phase III trial of its simplified four-dose YSJA rabies vaccine regimen. This aims to improve patient adherence and reduce costs while maintaining immunogenicity.

Portfolio Pulse from Benzinga Newsdesk

October 25, 2024 | 12:34 pm

In Wednesday's pre-market session, several healthcare stocks experienced significant price movements. CNS Pharma, DBV Technologies, and Cyclacel Pharmaceuticals were among the top gainers, while Alto Neuroscience and Ensysce Biosciences saw notable declines.

Portfolio Pulse from Benzinga Insights

October 23, 2024 | 12:08 pm

In Wednesday's pre-market session, several healthcare stocks experienced significant price movements. CNS Pharma, DBV Technologies, and Cyclacel Pharmaceuticals saw substantial gains, while Alto Neuroscience and Ensysce Biosciences faced notable declines.

Portfolio Pulse from Benzinga Insights

October 23, 2024 | 12:07 pm

In Friday's pre-market session, several healthcare stocks experienced significant movements. Notable gainers included NewGenIvf Group (NIVF) with a 71.8% increase, Conduit Pharmaceuticals (CDT) up by 40.77%, and Kindly MD (KDLY) rising by 17.76%. On the losing side, Carmell (CTCX) fell by 12.4%, Jin Medical International (ZJYL) decreased by 8.74%, and LakeShore Biopharma (LSB) dropped by 8.14%.

Portfolio Pulse from Benzinga Insights

October 11, 2024 | 12:07 pm

LakeShore Biopharma shares rose following the announcement of preliminary H1 2025 financial results and guidance.

Portfolio Pulse from Benzinga Newsdesk

October 08, 2024 | 1:52 pm

LakeShore Biopharma reported preliminary first-half revenue of RMB350M-RMB380M, indicating a growth of 28-39%.

Portfolio Pulse from Benzinga Newsdesk

October 08, 2024 | 12:34 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.